Jubilant Pharmova

Jubilant Pharmova's Radiopharma business announced an investment of CAD 94.5 million to modernise and expand its Kirkland, Quebec facility and double production capacity of its flagship RUBY-FILL cardiac PET product. The Government of Canada committed CAD 23.8 million to the project through the Strategic Response Fund's innovation funding stream. The Kirkland site was the only facility in Canada producing these radiopharmaceutical categories, and the company said its RUBY-FILL customer base doubled in the last three years. Radiopharma accounted for about 46% of consolidated revenue of Rs 8,280 crore in the year to March 2026, with 45 radiopharmacies in the United States and revenue of Rs 1,021 crore in the June quarter, up 17% from a year earlier. Ruby-Fill installations rose 26% on an annualised basis in that quarter. The company spent about Rs 1,668 crore on capital expenditure in FY26 and carried net debt of Rs 1,952 crore at the end of March. It employed around 5,500 people across its global pharmaceutical businesses.

Powered by Tijori

Oct 7 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - TO CONSIDER RAISING OF FUNDS THROUGH ISSUANCE OF NON- CONVERTIBLE DEBENTURES

Source text: ID:nBSE11CvLb

Further company coverage: JUBA.NS

(([email protected];))

Sept 11 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• USFDA CLASSIFIES JUBILANT HOLLISTERSTIER SPOKANE FACILITY AS VOLUNTARY ACTION INDICATED

Further company coverage: JUBA.NS

(([email protected];))

** Shares of Jubilant Pharmova JUBA.NS rise as much as 5.4%, last up 1% at 890 rupees

** The drugmaker's unit gets USFDA approval for its new isolator based fill and finish line, line three at contract manufacturing facility, Spokane, U.S.A

** Stock set to rise for a fourth straight session

** YTD, JUBA down ~18%

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Jubilant Pharmova received USFDA approval for commercial batch manufacturing of the first product on the new isolator-based fill-and-finish Line 3 at its Spokane, Washington, contract manufacturing facility. The approval was received on August 21, 2026, at 12:46pm Pacific time, equivalent to August 22 at 1:16am IST. Spokane generated ₹494 crore of revenue in the first quarter of FY27, up 43% from a year earlier, with an EBITDA margin of 24%. The site’s Line 3 had more than 10 technology-transfer products, while installation of Line 4 was complete.

Powered by Tijori

Jubilant Pharmova will hold one-on-one and group meetings with institutional investors in Mumbai on August 13-14, organized by Emkay Global Financial Services as part of its Emkay Confluence conference. The participant list includes HDFC AMC, ICICI Prudential AMC, Karma Capital, Motilal Oswal AMC, ICICI Prudential Life Insurance, ITI Mutual Fund, Tata Asset Management, and MK Ventures. The management will discuss the Q1 FY27 earnings presentation, which is to be filed on August 10 alongside the quarterly results. Jubilant Pharmova is a multi-platform pharmaceutical group spanning radiopharma, CDMO sterile injectables and CRDMO businesses, with FY26 consolidated revenue of ₹8,280 crore.

Powered by Tijori

May 22 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• MARCH-QUARTER CONSOL NET PROFIT 1.19 BILLION RUPEES

• DECLARES DIVIDEND OF 5 RUPEES PER SHARE

• MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 22.90 BILLION RUPEES

Source text: [ID:]

Further company coverage: JUBA.NS

(([email protected];))

Feb 6 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• DEC-QUARTER CONSOL NET PROFIT 559 MILLION RUPEES

• DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 21.23 BILLION RUPEES

Source text: [ID:]

Further company coverage: JUBA.NS

(([email protected];))

Dec 31 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• RECEIVES TAX DEMAND ORDER FOR 221 MILLION RUPEES

Source text: ID:nBSE96N8vw

Further company coverage: JUBA.NS

(([email protected];))

July 29 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA JUNE-QUARTER CONSOL NET PROFIT 1.03 BILLION RUPEES

• JUBILANT PHARMOVA JUNE-QUARTER CONSOL INCOME FROM OPERATIONS 18.79 BILLION RUPEES

Further company coverage: JUBA.NS

(([email protected];))

** Jubilant Pharmova JUBA.NS rises 4% to 942 rupees, highest in three weeks

** Drugmaker posts Q4 consol net profit of 1.54 bln rupees ($18 mln) vs year-ago loss of 586 mln rupees, which included a one time charge of 1.69 bln rupees

** Still, profit before one-time charge up 82% y/y

** Rev rises 10% y/y, driven by strong demand for co's drugs with radioactive ingredients

** JUBA was up 0.3% before results

** Volumes pick up post results, with shares traded ~3x the 30-day avg

** YTD, JUBA falls 18%

($1 = 85.6350 Indian rupees)

(Reporting by Nishit Navin in Bengaluru)

March 20 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA -JUBILANT BIOSYS SUBSCRIBES TO 80% EQUITY CAPITAL IN JASMIN

• JUBILANT PHARMOVA - JASMIN ACQUIRES PF'S RESEARCH AND DEVELOPMENT CENTRE AT SAINT JULIEN, FRANCE

Source text: ID:nBSELLpWh

Further company coverage: JUBA.NS

(([email protected];))

** Shares of Jubilant Pharmova JUBA.NS jump 2% to 882.30 rupees

** U.S. FDA completes inspection of drugmaker's manufacturing site in Maryland, classifies it as "voluntary action indicated"

** VAI indicates the agency is not prepared to take or recommend any administrative or regulatory action, per the FDA website

** Stock down 21% this year after doubling in 2024

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

March 12 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA LTD - JUBILANT CADISTA FACILITY RECEIVES EIR WITH VAI STATUS FROM USFDA

• JUBILANT PHARMOVA LTD - INSPECTION SUCCESSFULLY CLOSED WITH EIR RECEIPT FROM USFDA

Source text: ID:nBSE6bCy94

Further company coverage: JUBA.NS

(([email protected];))

Jan 31 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA Q3 CONSOL NET PROFIT 1.01 BILLION RUPEES

• JUBILANT PHARMOVA Q3 CONSOL INCOME FROM OPERATIONS 18.14 BILLION RUPEES

Source text: ID:nnAPN2LULWB

Further company coverage: JUBA.NS

(([email protected];;))

Jan 24 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• UNIT VOLUNTARY PREPAYS $25 MILLION TERM LOAN

Source text: ID:nBSEbSzP5v

Further company coverage: JUBA.NS

(([email protected];;))

Oct 29 (Reuters) - Ion Beam Applications SA IBAB.BR:

• PARTNERS WITH JUBILANT RADIOPHARMA, SELLING FIVE CYCLONE KIUBE

• SIGNING OF CONTRACT FOR INSTALLATION OF FIVE CYCLONE KIUBE 180 CYCLOTRONS AND ASSOCIATED EQUIPMENT IN U.S

Source text: https://shorturl.at/uAFNy

Further company coverage: IBAB.BR

(Gdansk Newsroom)

(([email protected]; +48 58 769 66 00;))

Oct 25 (Reuters) - India's Jubilant Pharmova JUBA.NS reported a 64.5% rise in second-quarter profit on Friday, driven by a strong demand for its drugs with radioactive ingredients, used to treat cancer and other diseases.

Consolidated net profit rose to 1.03 billion rupees (about $12 million) in the quarter ended Sept. 30 from 625 million rupees a year ago.

Revenue rose 4.5% to 17.42 billion rupees, lifted by the radiopharma segment's nearly 11% growth in this quarter.

The drugmaker, which manufactures and supplies radiopharmaceuticals used to diagnose and treat cancer and other diseases such as hyperthyroidism and lung diseases, has a network of 52 radio-pharmacies in the United States.

This business accounted for nearly 50% of the total revenue.

Revenue from its contract manufacturing segment, the firm's second biggest segment which makes sterile injectables, rose 5%.

Shares of the company turned positive after results and rose as much as 2% before paring most gains to trade flat.

($1 = 84.0540 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Sumana Nandy)

(([email protected]; 8800437922;))

Oct 10 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA- UNIT’S RECTIFICATION APPLICATION LED TO DELETION OF 381.3 MILLION RUPEES TAX DEMAND

Source text for Eikon: ID:nBSE8gg2C6

Further company coverage: JUBA.NS

(([email protected];))

Oct 4 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JBIRSPL TO ACQUIRE 80% EQUITY CAPITAL IN JASMIN FOR UPTO 4.4 MILLION EURO

• JASMIN TO ACQUIRE PIERRE FABRE’S RESEARCH AND DEVELOPMENT CENTRE AT SAINT JULIEN, FRANCE

Source text for Eikon: ID:nNSE76LCtq

Further company coverage: JUBA.NS

(([email protected];;))

Sept 26 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - COMPLETION OF USFDA AUDIT OF ALLERGY IMMUNOTHERAPY FACILITY, SPOKANE

• JUBILANT PHARMOVA - INSPECTION CONCLUDED WITH NO OBSERVATIONS

• JUBILANT PHARMOVA - COMPLETION OF USFDA AUDIT OF CONTRACT MANUFACTURING FACILITY LOCATED AT SPOKANE

Source text for Eikon: ID:nBSEgl7Z3

Further company coverage: JUBA.NS

(([email protected];;))

** Shares of Jubilant Pharmova JUBA.NS rise as much as 4.1%, last up 1.2% to 1,030 rupees

** Co says U.S. FDA's inspection of its U.S. contract manufacturing facility classified as "Voluntary Action Indicated"

** VAI indicates the agency is not prepared to take or recommend any administrative or regulatory action, per the U.S. FDA website

** Stock on track to rise in six out of seven straight sessions if trend holds

** JUBA up 89% YTD

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Sept 10 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - USFDA INSPECTION CLASSIFICATION OF UNIT'S FACILITY AS VOLUNTARY ACTION INDICATED

Source text for Eikon: ID:nBSE5S1Wvd

Further company coverage: JUBA.NS

(([email protected];))

** Shares of Jubilant Pharmova JUBA.NS climb ~5% to 899 rupees, their highest since May 2021

** Drugmaker's subsidiary issues "put option offer" to Pierre Fabre Laboratories to acquire 80% stake in a new company for 4.4 mln euros ($5 mln) to be incorporated in France

**Says, new co will buy Pierre Fabre's R&D centre

** Pierre Fabre will hire services from co's Jubilant Biosys unit up to 7 mln euros for first four years

** JUBA up ~65% YTD vs ~46% last year

($1 = 0.9054 euros)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Aug 16 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA - UNIT SIGNED, ISSUED "PUT OPTION OFFER" TO PIERRE FABRE LABORATORIES

• JUBILANT PHARMOVA - OFFER TO ACQUIRE 80% CAPITAL IN NEW CO TO BE INCORPORATED IN FRANCE

• JUBILANT PHARMOVA - UNIT TO INVEST UPTO EURO 14.4 MILLION IN 7 YEARS

Source text for Eikon: ID:nNSE4WJsVk

Further company coverage: JUBA.NS

(([email protected];))

BENGALURU, July 19 (Reuters) - Indian pharmaceutical firm Jubilant Pharmova JUBA.NS reported a nearly four-fold rise in first-quarter adjusted profit on Friday, boosted by strong demand for its drugs that contain radioactive ingredients.

The company's consolidated net profit before exceptional items and taxes rose to 1.04 billion rupees ($12.4 million) in the three months ended June 30 from 252 million rupees a year earlier.

The company had a one-time gain of 3.96 billion rupees after the sale of one of its units in the United States.

The company's shares rose as much as 10% after the results to a three-year high of 800 rupees, before paring most of the gains.

Analysts expect consistent growth in the company's high-margin radiopharma segment to drive revenue growth.

Jubilant Pharmova is involved in the manufacturing and supply of radiopharmaceuticals with a network of 46 radio-pharmacies in the United States. The company said it will invest $50 million to add six sites in its radiopharmacy network.

Total revenue rose 9% to 17.32 billion rupees, lifted by a 20.5% rise in the radiopharma segment. The business, which involves developing radioactive medications used to diagnose or treat cancer, accounted for more than 48% of the total revenue.

Revenue from its contract manufacturing segment, its second-biggest, also climbed 13% to 3.34 billion rupees.

($1 = 83.6250 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Subhranshu Sahu and Sohini Goswami)

(([email protected]; 8800437922;))

** Shares of Jubilant Pharmova JUBA.NS slide as much as 6%, before finishing the day 2.5% lower

** Pharma company says US FDA closed inspection of Montreal manufacturing facility with 15 observations, which indicates likely regulatory violations

** US FDA has issued three observations on a Washington facility last week

** Stock has gained 34.5% YTD

(Reporting by Nishit Navin)

(([email protected];))

June 14 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• UNIT ANNOUNCED AN INVESTMENT OF $50 MILLION TO EXPAND ITS PET RADIOPHARMACY NETWORK

• ADDING SIX PET RADIOPHARMACIES IN STRATEGIC LOCATIONS THROUGHOUT UNITED STATES

• INVESTMENT WILL EXPAND CO'S PET RADIOPHARMACY NETWORK TO NINE SITES, OVERALL RADIOPHARMACY NETWORK TO FIFTY TWO SITES

Further company coverage: JUBA.NS

(([email protected];))

** Shares of Jubilant Pharmova JUBA.NS fall as much as 3.3% to 732.35 rupees; last down 1.7%

** The pharmaceuticals company said on Friday that the U.S. Food and Drug Administration (USFDA) closed an inspection at its contract manufacturing facility in Washington with three observations

** More than 271,000 shares traded by 02:30 p.m. IST, 0.8x times their 30-day avg

** JUBA on track to snap three straight sessions of gains, if current trends hold

** Including session's move, stock is up 36.4% YTD

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

June 7 (Reuters) - Jubilant Pharmova Ltd JUBA.NS:

• JUBILANT PHARMOVA LTD - ANNOUNCES COMPLETION OF USFDA AUDIT OF CONTRACT MANUFACTURING FACILITY AT SPOKANE, WASHINGTON

• JUBILANT PHARMOVA LTD - USFDA HAS ISSUED 3 OBSERVATIONS PURSUANT TO COMPLETION OF AUDIT

• JUBILANT PHARMOVA LTD - COMPANY WILL SUBMIT AN ACTION PLAN ON OBSERVATIONS

Source text for Eikon: ID:nBSE210hpx

Further company coverage: JUBA.NS

(([email protected];))